Revenue growth remains under pressure with a 25.5% year-over-year decline in 2026Q2, while gross margins continue to exhibit volatility, fluctuating between a high of 50.7% in 2024Q3 and a low of 32.5% in 2025Q4.
| Sales/Revenue | 285.11M | 333.3M | 464.83M | 419.45M | 328.46M | 206.7M | 172.35M | 160.31M | 133.49M | 93.71M |
| Revenue Growth % | -28.69% | -28.3% | 10.82% | 27.7% | 58.91% | 19.93% | 7.51% | 20.09% | 42.46% | - |
| Cost of Goods Sold | 175.48M | 203.1M | 283.24M | 239.2M | 202.02M | 115.82M | 92.86M | 86.68M | 77.09M | 59.86M |
| COGS % of Revenue | - | 60.94% | 60.93% | 57.03% | 61.51% | 56.03% | 53.88% | 54.07% | 57.75% | 63.88% |
| Gross Profit | 109.63M | 130.2M | 181.59M | 180.25M | 126.44M | 90.88M | 79.49M | 73.62M | 56.4M | 33.85M |
| Gross Margin % | 38.45% | 39.06% | 39.07% | 42.97% | 38.49% | 43.97% | 46.12% | 45.93% | 42.25% | 36.12% |
| Gross Profit Growth % | - | -28.3% | 0.74% | 42.56% | 39.12% | 14.33% | 7.97% | 30.55% | 66.62% | - |
| Operating Expenses | 108.01M | 133.9M | 136.77M | 111.76M | 84.91M | 49.97M | 41.32M | 41.83M | 38.55M | 41.32M |
| OpEx % of Revenue | - | 40.17% | 29.42% | 26.64% | 25.85% | 24.18% | 23.98% | 26.1% | 28.88% | 44.09% |
| Selling, General & Admin | 72.84M | 88.35M | 94.27M | 85.54M | 57.36M | 44.39M | 29.48M | 30.84M | 35.26M | 27.39M |
| SG&A % of Revenue | - | 26.51% | 20.28% | 20.39% | 17.46% | 21.47% | 17.1% | 19.24% | 26.42% | 29.23% |
| Research & Development | 14.37M | 14.91M | 17.18M | 15.35M | 6.95M | 5.62M | 4.2M | 3.69M | 3.95M | 3.98M |
| R&D % of Revenue | - | 4.47% | 3.7% | 3.66% | 2.12% | 2.72% | 2.43% | 2.3% | 2.96% | 4.25% |
| Other Operating Expenses | 2M | 45.55M | 25.32M | 10.87M | 20.6M | -34.25K | 7.65M | 0 | 0 | 0 |
| Operating Income | 1.62M | -3.7M | 44.82M | 54.18M | 39.87M | 38.38M | 39.15M | 32.09M | 15.71M | -706.92K |
| Operating Margin % | 0.57% | -1.11% | 9.64% | 12.92% | 12.14% | 18.57% | 22.71% | 20.01% | 11.77% | -0.75% |
| Operating Income Growth % | - | -108.26% | -17.28% | 35.9% | 3.87% | -1.95% | 22% | 104.22% | 2322.44% | - |
| EBITDA | 19.03M | 13.69M | 66.12M | 73.57M | 49.06M | 44.65M | 43.88M | 36.91M | 20.08M | 3.9M |
| EBITDA Margin % | 6.68% | 4.11% | 14.22% | 17.54% | 14.94% | 21.6% | 25.46% | 23.03% | 15.04% | 4.16% |
| EBITDA Growth % | -68.17% | -79.29% | -10.14% | 49.98% | 9.88% | 1.75% | 18.87% | 83.8% | 415.03% | - |
| D&A (Non-Cash Add-back) | 17.41M | 17.39M | 21.3M | 19.39M | 9.19M | 6.26M | 4.73M | 4.83M | 4.37M | 4.61M |
| EBIT | -5.6M | -3.8M | 34.16M | 52.99M | 38.73M | 37.44M | 25.84M | 12.46M | -12.77K | -706.92K |
| Net Interest Income | -47.88M | -50.1M | -26.87M | -23.79M | -17.93M | -21.24M | -11.66M | -44.34M | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 7.73M | 1.49M | 0 | 14.92M |
| Interest Expense | 47.88M | 50.1M | 26.87M | 23.79M | 17.93M | 21.24M | 19.4M | 21.84M | 0 | 0 |
| Other Income/Expense | -55.15M | -50.2M | -34.78M | -35.08M | -25.81M | -27.85M | 0 | -41.46M | -40.95M | -21.68M |
| Pretax Income | -53.53M | -53.9M | 10.04M | 19.11M | 14.06M | 10.53M | 6.44M | -9.37M | -25.24M | -22.39M |
| Pretax Margin % | -18.77% | -16.17% | 2.16% | 4.55% | 4.28% | 5.09% | 3.74% | -5.85% | -18.91% | -23.9% |
| Income Tax | 7.99M | 1.3M | 3.78M | -1.07M | 17.97M | 14.35M | 2.21M | 6.99M | -10.93M | -5.63M |
| Effective Tax Rate % | -14.92% | -2.41% | 37.66% | -5.59% | 127.79% | 136.28% | 34.25% | -74.54% | 43.3% | 25.16% |
| Net Income | -235.97M | -51.8M | 3.24M | 18.78M | -7.2M | -6.87M | 3.36M | -18.37M | -11.04M | -11.82M |
| Net Margin % | -82.77% | -15.54% | 0.7% | 4.48% | -2.19% | -3.32% | 1.95% | -11.46% | -8.27% | -12.61% |
| Net Income Growth % | -15822.86% | -1697.29% | -82.73% | 360.85% | -4.8% | -304.52% | 118.29% | -66.39% | 6.59% | - |
| Net Income (Continuing) | -61.51M | -55.2M | 6.26M | 20.17M | -3.91M | -3.82M | 1.76M | -16.36M | -14.31M | -16.76M |
| Discontinued Operations | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 32.85M | 32.41M | 36.08M | 31.65M | 30.68M | 22.55M | 14.57M | 14.79M | 19.42M | 41.4M |
| EPS (Diluted) | -3.72 | -0.82 | 0.05 | 0.30 | -0.17 | -0.18 | 0.09 | -0.60 | -0.39 | -0.42 |
| EPS Growth % | -12974.39% | -1704.7% | -82.97% | 276.47% | 5.56% | -295.23% | 115.37% | -53.85% | 7.14% | - |
| EPS (Basic) | - | -0.82 | 0.05 | 0.30 | -0.17 | -0.18 | 0.09 | -0.60 | -0.39 | -0.42 |
| Diluted Shares Outstanding | 63.48M | 63.2M | 63.48M | 63.19M | 42.3M | 39.22M | 36.42M | 30.48M | 28.1M | 28.1M |
| Basic Shares Outstanding | 63.48M | 63.2M | 62.84M | 62.15M | 42.3M | 39.22M | 36.12M | 30.48M | 28.1M | 28.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Argentine macroeconomic volatility exposure
As indicated by recent financial disclosures, BIOX has experienced a sustained period of top-line decline, with revenue falling to $73.7M in 2026Q2, representing a 25.5% year-over-year contraction that highlights the significant challenges in maintaining growth momentum within its core Argentine agricultural input markets.
The consistent downward trajectory in quarterly revenue suggests that the company is struggling to offset cyclical headwinds or potential delays in the commercial adoption of its HB4 technology. Investors should monitor whether this trend reflects a structural saturation in local markets or temporary disruptions in the identity-preserved supply chain.
Based on reported figures, gross margins have exhibited significant volatility, fluctuating between a high of 50.7% in 2024Q3 and a low of 32.5% in 2025Q4, which underscores the sensitivity of the company's product mix to seasonal pricing pressures and shifting input costs.
The inability to maintain a stable gross margin profile suggests that the company lacks consistent pricing power in its Crop Protection and Nutrition segments. This variability complicates the path to profitability, as the high-margin HB4 seed segment has yet to achieve the scale necessary to stabilize overall corporate margins.
According to the income statement data, the company has failed to demonstrate positive operating leverage, as evidenced by the 2025Q4 operating loss of $14.9M despite significant gross profit generation, suggesting that overhead costs remain disproportionately high relative to the current revenue scale.
The persistent gap between gross profit and operating income indicates that SG&A and R&D expenditures are not scaling efficiently with sales volume. This structure implies that the company may require a substantial increase in revenue to reach a sustainable operating breakeven point.
As reported in financial statements, the company's net income has been characterized by extreme volatility, including a significant $183.0M loss in 2026Q2, which appears to be driven by non-operating items and potential accounting adjustments rather than core operational performance alone.
The wide disparity between operating income and net income warrants further investigation into the impact of hyperinflationary accounting and non-operating charges. Investors should be cautious of relying on EPS as a performance metric given the frequent, large-scale adjustments that obscure the underlying cash-generating capability of the business.
Quick answers to the most common questions about buying BIOX stock.
For fiscal year 2025, Bioceres Crop Solutions Corp. (BIOX) reported total revenue of $333.3M. This represents a 255.7% increase compared to $93.7M in 2017.
Bioceres Crop Solutions Corp. (BIOX) reported a net loss of $51.8M for the fiscal year ending 2025.
Bioceres Crop Solutions Corp. (BIOX) reported an operating income of $-3.7M, resulting in an operating profit margin of -1.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Bioceres Crop Solutions Corp. (BIOX) generated $130.2M in gross profit for the year, representing a gross profit margin of 39.1%. This demonstrates the company's core pricing power and production efficiency.